Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
29 hedge funds and large institutions have $18.9M invested in Telesis Bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
63% more call options, than puts
Call options by funds: $70K | Put options by funds: $43K
12% more funds holding
Funds holding: 26 → 29 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
49% less capital invested
Capital invested by funds: $37.3M → $18.9M (-$18.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$78.2K |
| 2 |
PM
Penbrook Management
New York
|
+$47.2K |
| 3 |
DDC
DF Dent & Co
Baltimore,
Maryland
|
+$44.3K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$31.7K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$7.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$205K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$94K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$32.6K |
| 4 |
Two Sigma Investments
New York
|
-$20.2K |
| 5 |
Renaissance Technologies
New York
|
-$6.87K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $430 | – | – | – |
|
27
Osaic Holdings
Scottsdale,
Arizona
| $355 | – | – | – |
|
28
Citadel Advisors
Miami,
Florida
| $201 | +$239 | +6 | +600% |
|
29
Wells Fargo
San Francisco,
California
| $101 | +$40 | +1 | +33% |
|
30
Citigroup
New York
| $9 | – | – | – |
|
|
31
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$94K | -2,354 | Closed |
|
|
TSS
32
Two Sigma Securities
New York
| – | -$32.6K | -584 | Closed |
|
TBIO Hedge Fund Activity: Q2 2023 in Review
29 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q2 2023, worth a combined $18.9M — down 49% from $37.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TBIO positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Penn Capital Management, adding an estimated $78.2K. The largest seller was Millennium Management, cutting an estimated $205K.
- 29 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q2 2023, up from 26 in Q1 2023.
- Funds reported $18.9M of Telesis Bio, Inc. Common Stock stock for Q2 2023, down 49% quarter-over-quarter.
- 5 funds opened new Telesis Bio, Inc. Common Stock positions in Q2 2023 and 2 closed out, a net change of +3 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q2 2023 was Penn Capital Management, an estimated $78.2K added.
- The largest Telesis Bio, Inc. Common Stock seller in Q2 2023 was Millennium Management, an estimated $205K sold.
Based on aggregated 13F filings for Q2 2023.